Agenus closed a previously announced $141 million strategic collaboration with Zydus Lifesciences to advance the botensilimab plus balstilimab (BOT+BAL) immunotherapy program. The deal secures committed U.S. biologics manufacturing capacity via Zydus and gives Zydus exclusive rights to develop and commercialize the program in India and Sri Lanka. Agenus said the transaction strengthens its balance sheet and supports Phase III execution, authorized early access programs, and commercial supply preparation for BOT+BAL in microsatellite‑stable colorectal cancer. The agreement also transfers Emeryville and Berkeley manufacturing sites to a Zydus subsidiary, Zylidac Bio, while protecting Agenus’ clinical supply needs. Agenus framed the partnership as a strategic move to derisk manufacturing and accelerate global development timelines as it pursues regulatory milestones. Source: GEN – Genetic Engineering & Biotechnology News coverage and company statements.